NEWS

NEWS

News

NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting A Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the Nant Cancer Vaccine

January 4, 2018 — Culver City, California — NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer,...

read more

NantKwest to Present at Upcoming Investment Conferences

CULVER CITY, CALIFORNIA - November 27, 2017 NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at several investment conference in the...

read more

NantKwest to Present at Upcoming Investment Conferences

CULVER CITY, CALIFORNIA-, September 5, 2017 NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at three investment conference in September. The presentations will feature...

read more

Categories

  • No categories

Archives

Media Contact:

Jen Hodson
NantKwest
Telephone: 562-397-3639
Email: Press@NantKwest.com